Status:
TERMINATED
Macugen Observational Study
Lead Sponsor:
Pfizer
Conditions:
Vascular Endothelial Growth Factor
Macular Degeneration
Eligibility:
All Genders
18-90 years
Brief Summary
The objective of this observational study is to evaluate the effectiveness and safety of Macugen for treatment of wet age-related macular degeneration (AMD) in Indian patients.Prospective, Observation...
Detailed Description
To be eligible for enrollment in this study, patients must receive the first injection of Macugen intravitreal in at least one eye for treatment of wet age-related macular degeneration (AMD). The deci...
Eligibility Criteria
Inclusion
- To be eligible for enrollment in this study, patients must receive the first injection of Macugen intravitreal in at least one eye for treatment of wet age-related macular degeneration (AMD).
Exclusion
- Active or suspected ocular or periocular infection.
- Known hypersensitivity to pegaptanib sodium or any other excipient in this product.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00735943
Start Date
November 1 2008
End Date
August 1 2010
Last Update
August 29 2011
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Navrangpura, Ahemdabad, Gujarat, India, 380009
2
Pfizer Investigational Site
Gurgaon, Haryana, India, 122 002
3
Pfizer Investigational Site
Kochi, Kerala, India, 682 015
4
Pfizer Investigational Site
Mumbai, Maharashtra, India, 400 054